The Full-Term Delivery of a Normal Female Infant by a Woman with a Levonorgestrel Intrauterine System in Situ and Identified as Having Uterine Adenomyosis: A Case Report

Zhou Liang¹, Mingru Yin¹, Ai Ai¹, Yun Wang¹, Qiuju Chen¹, Songguo Xue¹ and Yanping Kuang^1,

¹Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China

Cite this paper

Zhou Liang, Mingru Yin, Ai Ai, Yun Wang, Qiuju Chen, Songguo Xue and Yanping Kuang. The Full-Term Delivery of a Normal Female Infant by a Woman with a Levonorgestrel Intrauterine System in Situ and Identified as Having Uterine Adenomyosis: A Case Report. American Journal of Medical Case Reports. 2017; 5(1):4-7. doi: 10.12691/AJMCR-5-1-2

Abstract

This study reports an IVF patient who had adenomyosis underwent 2 in vitro fertilization (IVF) cycles and 3 frozen embryo transfer (FET) cycles but all failed. Then a Levonorgestrel-releasing intrauterine system (LNG-IUS) was inserted into her uterine. When her next menstrual period did not occur, the patient performed a urinary pregnancy test and it was positive. The pregnancy progressed normally and the delivery was uncomplicated. An elective Caesarean delivery was performed at 39 weeks gestation. The IUD was found in the placenta and the postpartum recovery was uneventful. This is the first report of a woman, who having been identified with uterine adenomyosis, delivered a normal female infant with an LNG-IUS in situ. This case report indicated that LNG-IUS may play some roles in changing the uterine environment of adenomyosis.

Keywords

Levonorgestrel-releasing intrauterine system, in vitro fertilization, adenomyosis

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Campo, S., V. Campo, and G. Benagiano, Infertility and adenomyosis. Obstet Gynecol Int, 2012. 2012: p. 786132.
[2]	Kuang, Y., et al., Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril, 2015. 104(1): p. 62-70 e3.
[3]	Kuang, Y., et al., Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online, 2014. 29(6): p. 684-91.
[4]	Kuang, Y., et al., Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril, 2014. 101(1): p. 105-11.
[5]	Chen, H., et al., Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril, 2015. 103(5): p. 1194-1201 e2.
[6]	Wang, N., et al., Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf), 2016. 84(5): p. 720-8.
[7]	Cox, M., J. Tripp, and S. Blacksell, Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care, 2002. 28(2): p. 73-7.
[8]	Champaneria, R., et al., Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy. Acta Obstet Gynecol Scand, 2010. 89(11): p. 1374-84.
[9]	Bragheto, A.M., et al., Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception, 2007. 76(3): p. 195-9.
[10]	Peng, F.S., et al., Insertion of the Mirena intrauterine system for treatment of adenomyosis-associated menorrhagia: a novel method. Taiwan J Obstet Gynecol, 2010. 49(2): p. 160-4.
[11]	Cho, S., et al., Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol, 2008. 198(4): p. 373 e1-7.
[12]	Sheng, J., et al., The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception, 2009. 79(3): p. 189-93.
[13]	Kim, S.K., et al., The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD). J Perinat Med, 2010. 38(1): p. 45-53.
[14]	WHO, Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser, 1987. 753: p. 1-91.
[15]	Backman, T., et al., Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol, 2004. 190(1): p. 50-4.
[16]	Budiman, H., et al., Pregnancy in a patient with a displaced levonorgestrel-releasing intrauterine system: a case report. Arch Gynecol Obstet, 2007. 276(3): p. 263-4.
[17]	Hopkins, M.R., et al., Term pregnancy with intraperitoneal levonorgestrel intrauterine system: a case report and review of the literature. Contraception, 2009. 79(4): p. 323-7.
[18]	McCarthy, E.A., et al., Ultrasound-guided hysteroscopy to remove a levonorgestrel intrauterine system in early pregnancy. Contraception, 2012. 86(5): p. 587-90.
[19]	Pilkington, A., N. Misfar, and D.W. Polson, Successful pregnancy outcome with the levonorgestrel-releasing intrauterine system. J Fam Plann Reprod Health Care, 2008. 34(1): p. 60.
[20]	Gardyszewska, A. and K. Czajkowski, [Application of levonorgestrel-releasing intrauterine system in early pregnancy: a case report]. Ginekol Pol, 2012. 83(12): p. 950-2.
[21]	Margalioth, E.J., et al., Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod, 2006. 21(12): p. 3036-43.
[22]	Tremellen, K. and P. Russell, Adenomyosis is a potential cause of recurrent implantation failure during IVF treatment. Aust N Z J Obstet Gynaecol, 2011. 51(3): p. 280-3.
[23]	Agarwal, A., S. Gupta, and R.K. Sharma, Role of oxidative stress in female reproduction. Reprod Biol Endocrinol, 2005. 3: p. 28.
[24]	Yun, B.H., et al., Effects of a Levonorgestrel-Releasing Intrauterine System on the Expression of Steroid Receptor Coregulators in Adenomyosis. Reprod Sci, 2015. 22(12): p. 1539-48.
[25]	Schardein, J.L., Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology, 1980. 22(3): p. 251-70.